Skip To Main Content
Marco Jochem on Muck Rack

Marco Jochem

As seen in: Nature, ScienceDirect, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Marco Jochem’s profile

Articles by Marco Jochem

Ubiquitination of glycogen and metabolites in cells and tissues

|
By Marco Jochem, Simon A. Cobbold, Craig Goodman, Catharina Kueng, Anthony Cerra, Laura F. Fielden, Man Lyang Kim, Philipp Schenk, Xiangyi Wang, Simon R. Scutts, Michael Pandos, Lin Tang, Thomas Hermanns, Shane Devine, Martin Brzozowski, Yuri Shibata, Niall Geoghegan, Catriona A. McLean, Bernhard Lechtenberg, Kay H Hofmann, Paul Gregorevic, David Komander
| Nature Verified
Abstract Ubiquitin signalling covers a wide range of protein modifications, but its scope may still be underestimated, owing to the ubiquitination of non-proteinaceous substrates, such as sugars, lipids and nucleotides1. The breadth of ubiquitinated non-protein substrates, their abundance and their cellular roles are currently unclear, as current ubiquitinomic and proteomic techniques do not detect non-proteinaceous modifications.
Open in Who Shared Issue with article?

Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma

|
By Marco Jochem, Jeroen Krijgsveld, Martijn S. Luijsterburg, Criseyda Martinez
| ScienceDirect Verified
Cytotoxic T lymphocytes (CTLs) with clonal amplification and reactivity characteristics are key effector cells for antitumor immunity; their infiltration typically represents a predictive biomarker of effective immune checkpoint blockade (ICB) treatment.1,2,3,4,5 However, only a small portion of patients with enriched tumor CTLs can benefit from ICB (anti-PD-1/PD-L1) therapy, and after receiving ICB therapy, some patients even experience hyperprogressive disease,6,7,8,9 indicating an...
Open in Who Shared Issue with article?

Degradome analysis to identify direct protein substrates of small-molecule degraders

|
By Marco Jochem, Anna Schrempf, Jose Cisneros, José A. Cisneros, Lina-Marie Wagner
| BioRxiv
Abstract Targeted protein degradation (TPD) has emerged as a powerful strategy to selectively eliminate cellular proteins using small-molecule degraders, offering therapeutic promise for targeting proteins that are otherwise undruggable. However, a remaining challenge is to unambiguously identify primary TPD targets that are distinct from secondary downstream effects in the proteome.
Open in Who Shared Issue with article?

Targeted Degradation of Glucose Transporters Protects against Arsenic Toxicity

|
By Marta Isasa, Marco Jochem, Lukas Ende, Jessie Ang
| asm.org
Research Article | Spotlight Marco Jochem, Lukas Ende, Marta Isasa, Jessie Ang, Helena Schnell, Angel Guerra-Moreno, Yagmur Micoogullari, Meera Bhanu, Steven P. Gygi, John Hanna DOI: 10.1128/MCB.00559-18 ABSTRACT The abundance of cell surface glucose transporters must be precisely regulated to ensure optimal growth under constantly changing environmental conditions.
Open in Who Shared Issue with article?
Show More